S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
86 shs
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$214.50

Seagen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
6.2% Downside
$214.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.63
Upright™ Environmental Score
News Sentiment
0.00mentions of Seagen in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.82) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.47 out of 5 stars

Medical Sector

906th out of 958 stocks

Biotechnology Industry

31st out of 37 stocks


SGEN stock logo

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.


SGEN Stock News Headlines

Seagen (NASDAQ:SGEN) Now Covered by Analysts at StockNews.com
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
SGEN Jan 2024 210.000 put
SGEN Jan 2024 235.000 put(CONTR
SGEN Dec 2023 195.000 put(CONTR
HBM Gets Health Boost From Drug Licensing Deals
What the Options Market Tells Us About Seagen
A Closer Look at Seagen's Options Market Dynamics
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$214.50
High Stock Price Target
$229.00
Low Stock Price Target
$129.00
Potential Upside/Downside
-6.2%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
11 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-32.12%

Debt

Sales & Book Value

Annual Sales
$2.30 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
Optionable
Beta
0.32

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy Seagen Stock? SGEN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Sunday, February 25, 2024 at 3:12 PM.

Pros

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. has a diverse portfolio of innovative cancer therapies, including ADCETRIS, PADCEV, and TUKYSA, targeting different types of cancer, providing potential for revenue growth.
  • Recent acquisition of Seagen Inc. shares by Hudson Bay Capital Management LP indicates investor confidence in the company's future prospects.
  • Seagen Inc. has collaboration agreements with reputable pharmaceutical companies like Takeda, Merck, and Genmab, enhancing its research and development capabilities.
  • Introduction of new products like TIVDAK, Ladiratuzumab Vedotin, and Disitamab Vedotin in the pipeline could drive future revenue streams and market expansion.
  • Seagen Inc.'s strategic shift towards expanding its product offerings and partnerships demonstrates a commitment to long-term growth and sustainability in the biotechnology sector.

Cons

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Market volatility and regulatory challenges in the biotechnology industry can impact Seagen Inc.'s stock price, leading to potential investment risks.
  • Competition from other biotech companies developing similar cancer therapies may pose a threat to Seagen Inc.'s market share and profitability.
  • Dependency on a few key products like ADCETRIS and PADCEV for a significant portion of revenue could expose Seagen Inc. to risks associated with product lifecycle and market acceptance.
  • Fluctuations in research and development costs, clinical trial outcomes, and regulatory approvals can affect Seagen Inc.'s financial performance and investor confidence.
  • Investors should carefully monitor the biotech industry landscape and Seagen Inc.'s product pipeline to assess potential risks and opportunities before making investment decisions.














SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price target for 2024?

11 brokerages have issued 1 year price targets for Seagen's stock. Their SGEN share price targets range from $129.00 to $229.00. On average, they anticipate the company's stock price to reach $214.50 in the next year. This suggests that the stock has a possible downside of 6.2%.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.33. The biotechnology company had revenue of $648.65 million for the quarter, compared to the consensus estimate of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The firm's revenue was up 27.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.03) EPS.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's major shareholders?

Seagen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Clear Street Markets LLC (0.00%), Public Sector Pension Investment Board (0.00%), Mint Tower Capital Management B.V. (0.00%), Neuberger Berman Group LLC (0.00%), Cowen AND Company LLC (0.00%) and Segantii Capital Management Ltd (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
This page (NASDAQ:SGEN) was last updated on 3/1/2024 by MarketBeat.com Staff